Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission.

[1]  A. Sinha,et al.  Detailed profiling of anti-desmoglein autoantibodies identifies anti-Dsg1 reactivity as a key driver of disease activity and clinical expression in pemphigus vulgaris , 2015, Autoimmunity.

[2]  J. Griss,et al.  Autoantibody Levels and Clinical Disease Severity in Patients with Pemphigus: Comparison of Aggregated Anti-desmoglein ELISA Values and Indirect Immunofluorescence Titres. , 2015, Acta dermato-venereologica.

[3]  D. Zillikens,et al.  Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV) , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  P. Wolkenstein,et al.  The Value of Anti-Desmoglein Enzyme-Linked Immunosorbent Assay in the Immunological Follow-Up of Pemphigus , 2014, Dermatology.

[5]  K. Kamyab,et al.  Comparison of desmoglein 1 and 3 enzyme‐linked immunosorbent assay and direct immunofluorescence for evaluation of immunological remission in pemphigus vulgaris , 2014, Clinical and experimental dermatology.

[6]  Y. Aoyama,et al.  A higher correlation of the antibody activities against the calcium-dependent epitopes of desmoglein 3 quantified by ethylenediaminetetraacetic acid-treated enzyme-linked immunosorbent assay with clinical disease activities of pemphigus vulgaris. , 2013, Journal of dermatological science.

[7]  V. Sharma,et al.  Utility of desmoglein ELISA in the clinical correlation and disease monitoring of pemphigus vulgaris , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  Y. Aoyama,et al.  Detection of antibodies against the non‐calcium‐dependent epitopes of desmoglein 3 in pemphigus vulgaris and their pathogenic significance , 2012, The British journal of dermatology.

[9]  Z. Naraghi,et al.  Direct immunofluorescence of plucked hair for evaluation of immunologic remission in pemphigus vulgaris. , 2011, Journal of the American Academy of Dermatology.

[10]  H. Mouquet,et al.  ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. , 2009, Archives of dermatology.

[11]  L. Vaillant,et al.  Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. , 2009, Archives of dermatology.

[12]  T. Nishikawa,et al.  Anti‐desmoglein IgG autoantibodies in patients with pemphigus in remission , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  H. Shimizu,et al.  Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. , 2008, Journal of the American Academy of Dermatology.

[14]  A. Khamesipour,et al.  Desmoglein 1 and 3 enzyme‐linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  A. Taheri,et al.  Value of direct immunofluorescence in predicting remission in pemphigus vulgaris , 2006, International journal of dermatology.

[16]  K. Harman,et al.  Guidelines for the management of pemphigus vulgaris , 2003, The British journal of dermatology.

[17]  P. Seed,et al.  The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels , 2001, The British journal of dermatology.

[18]  S. Challacombe,et al.  A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype , 2000, The British journal of dermatology.

[19]  K. V. Ratnam,et al.  Pemphigus in remission: value of negative direct immunofluorescence in management. , 1994, Journal of the American Academy of Dermatology.

[20]  A. Ingber,et al.  The usefulness of immunofluorescent tests in pemphigus patients in clinical remission , 1989, The British journal of dermatology.

[21]  H. Mescon,et al.  Comparison of different epithelial substrates useful for indirect immunofluorescence testing of sera from patients with active pemphigus. , 1979, The Journal of investigative dermatology.

[22]  W. F. Lever,et al.  Correlation of antibodies in skin and serum with disease severity in pemphigus. , 1979, Archives of dermatology.